| abstract |
The present invention relates to a biocompatible liquid alginate biomaterial, for use in the treatment of impaired liver function in a subject in need thereof, said impaired liver function resulting from fulminant hepatic failure, hepatectomy and/or a liver disease selected from the group consisting of autoimmune hepatitis, chronic hepatitis C, chronic hepatitis B, primary biliary cirrhosis, primary sclerosing cholangitis, sarcoidosis and biliary atresia. |